Predictors of 6-month clinical change in primary progressive aphasia following language therapy and transcranial magnetic stimulation
Abstract
Primary progressive aphasia (PPA) is a neurodegenerative disorder characterized by progressive language impairment. Available treatments and information on factors associated with clinical change and treatment response remain limited. This study is a post hoc analysis of a randomized controlled trial and aimed to identify baseline demographic, cognitive and neuroimaging factors associated with clinical change in a subanalysis of a double-blind, randomized, parallel clinical trial of transcranial magnetic stimulation (TMS) and language therapy in PPA. Fifty-seven patients diagnosed with PPA received 6 months of lexical retrieval treatment, 40 with active TMS and 17 with sham TMS. All participants underwent comprehensive cognitive and language assessments before treatment and were evaluated using the Mini Linguistic State Examination (MLSE), naming task, words per minute, the Interview for Deterioration in Daily Living Activities in Dementia (IDDD), the Neuropsychiatric Inventory (NPI) and fluorodeoxyglucose-PET scans before and after treatment. Predictors of clinical change were analysed using least absolute shrinkage and selection operator (LASSO) and Elastic Net regression models, and unsupervised k-means clustering was applied to identify response profiles. Models for MLSE (LASSO: R2 = 0.52; Elastic Net: R2 = 0.57), naming (LASSO: R2 = 0.42; Elastic Net: R2 = 0.41), IDDD (LASSO: R2 = 0.46; Elastic Net: R2 = 0.58) and NPI (LASSO: R2 = 0.81; Elastic Net: R2 = 0.77) demonstrated good predictive accuracy. TMS treatment consistently emerged as the strongest predictor of clinical improvement across all outcomes. Higher metabolism in several brain regions (left hippocampus, posterior cingulate and orbitofrontal cortex) predicted greater clinical improvement. Cluster analysis identified two subgroups: responders and non-responders, with 77.5% of patients receiving active TMS in the responder cluster and 82.4% of the sham group in the non-responder cluster. Among patients receiving active TMS, a positive effect was associated with the non-fluent and semantic variants and with better cognitive performance in non-language domains. In conclusion, TMS treatment emerged as the main factor associated with clinical improvement on cognitive-linguistic and functional measures. Better cognitive performance and preserved brain metabolism in key regions were linked to more favourable clinical outcomes. These findings underscore the potential of TMS in combination with language therapy and pave the way for precision medicine approaches in PPA, emphasizing the need to identify individual profiles that predict optimal treatment response.
Related
- Repetitive transcranial magnetic stimulation paired with a 3D-printed ankle-foot orthosis for ankle-foot dysfunction among older adults following subacute stroke: clinical findings and exploratory neurophysiological analyses
- Global clinical development of transcranial temporal interference stimulation: an analysis of registered human trials
- Effects of repetitive transcranial magnetic stimulation on quality of postoperative recovery following major abdominal surgery: a study protocol for a single-center, prospective, randomized controlled trial
- Improved inhibitory control following combined transcranial direct current stimulation (tDCS) and cognitive training in individuals with traumatic brain injury and impulsivity
- EEG-defined differences in functional networks following beta-band transcranial alternating current stimulation in patients with disorders of consciousness: a pilot study.
BibTeX
@article{fernandezromero2026predictors,
title = {{Predictors of 6-month clinical change in primary progressive aphasia following language therapy and transcranial magnetic stimulation}},
author = {Lucía Fernández-Romero and Cristina Delgado-Alonso and Stephanie M Grasso and María Nieves Cabrera-Martín and Paloma Balugo and Adela Fraile-Pereda and Paz Suárez-Coalla and Yadhira Barroso and Silvia Oliver-Mas and Jorge Matias-Guiu and Javier Olazarán and María Díez-Cirarda and Jordi A Matias-Guiu},
journal = {Brain Communications},
year = {2026},
month = oct,
doi = {10.1093/braincomms/fcag398},
url = {https://doi.org/10.1093/braincomms/fcag398},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Predictors of 6-month clinical change in primary progressive aphasia following language therapy and transcranial magnetic stimulation
AU - Lucía Fernández-Romero
AU - Cristina Delgado-Alonso
AU - Stephanie M Grasso
AU - María Nieves Cabrera-Martín
AU - Paloma Balugo
AU - Adela Fraile-Pereda
AU - Paz Suárez-Coalla
AU - Yadhira Barroso
AU - Silvia Oliver-Mas
AU - Jorge Matias-Guiu
AU - Javier Olazarán
AU - María Díez-Cirarda
AU - Jordi A Matias-Guiu
PY - 2026
DA - 2026/10/19
JO - Brain Communications
DO - 10.1093/braincomms/fcag398
UR - https://doi.org/10.1093/braincomms/fcag398
AB - Primary progressive aphasia (PPA) is a neurodegenerative disorder characterized by progressive language impairment. Available treatments and information on factors associated with clinical change and treatment response remain limited. This study is a post hoc analysis of a randomized controlled trial and aimed to identify baseline demographic, cognitive and neuroimaging factors associated with clinical change in a subanalysis of a double-blind, randomized, parallel clinical trial of transcranial magnetic stimulation (TMS) and language therapy in PPA. Fifty-seven patients diagnosed with PPA received 6 months of lexical retrieval treatment, 40 with active TMS and 17 with sham TMS. All participants underwent comprehensive cognitive and language assessments before treatment and were evaluated using the Mini Linguistic State Examination (MLSE), naming task, words per minute, the Interview for Deterioration in Daily Living Activities in Dementia (IDDD), the Neuropsychiatric Inventory (NPI) and fluorodeoxyglucose-PET scans before and after treatment. Predictors of clinical change were analysed using least absolute shrinkage and selection operator (LASSO) and Elastic Net regression models, and unsupervised k-means clustering was applied to identify response profiles. Models for MLSE (LASSO: R2 = 0.52; Elastic Net: R2 = 0.57), naming (LASSO: R2 = 0.42; Elastic Net: R2 = 0.41), IDDD (LASSO: R2 = 0.46; Elastic Net: R2 = 0.58) and NPI (LASSO: R2 = 0.81; Elastic Net: R2 = 0.77) demonstrated good predictive accuracy. TMS treatment consistently emerged as the strongest predictor of clinical improvement across all outcomes. Higher metabolism in several brain regions (left hippocampus, posterior cingulate and orbitofrontal cortex) predicted greater clinical improvement. Cluster analysis identified two subgroups: responders and non-responders, with 77.5% of patients receiving active TMS in the responder cluster and 82.4% of the sham group in the non-responder cluster. Among patients receiving active TMS, a positive effect was associated with the non-fluent and semantic variants and with better cognitive performance in non-language domains. In conclusion, TMS treatment emerged as the main factor associated with clinical improvement on cognitive-linguistic and functional measures. Better cognitive performance and preserved brain metabolism in key regions were linked to more favourable clinical outcomes. These findings underscore the potential of TMS in combination with language therapy and pave the way for precision medicine approaches in PPA, emphasizing the need to identify individual profiles that predict optimal treatment response.
SN - 2632-1297
ER -